ArticleBritish journal of cancer2017
Clinical value of R-spondins in triple-negative and metaplastic breast cancers.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- RSPO2-induced ferroptosis via PTBP1-mediated FSP1 mRNA decay suppresses breast cancer progression.Frontiers in oncology · 2026Article
- RSPO4 exerts tumor suppression through antagonizing canonical and non-canonical Wnt signaling.International journal of biological sciences · 2026Article
- Hierarchical clustering defines hypermethylated RSPO2 as early-stage potential biomarker in colorectal cancer.Global medical genetics · 2025Article
- RSPO2 as Wnt signaling enabler: Important roles in cancer development and therapeutic opportunities.Genes & diseases · 2024Review
- R-spondin family biology and emerging linkages to cancer.Annals of medicine · 2023Review
- Article
- Latest advances in the study of non-coding RNA-mediated circadian rhythm disorders causing endometrial cancer.Frontiers in oncology · 2023Review
- R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer.The Journal of pathology · 2022Article
- The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs.Cancer gene therapy · 2022Article
- RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis.The Journal of clinical investigation · 2022Article
- Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.Frontiers in molecular biosciences · 2022Article
- The role of R-spondin proteins in cancer biology.Oncogene · 2021Review
- Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer.Frontiers in cell and developmental biology · 2021Review
- R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers.DNA and cell biology · 2021Article
- Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.Molecular cancer · 2020Review
- Associated analysis of PER1/TUBB2B with endometrial cancer development caused by circadian rhythm disorders.Medical oncology (Northwood, London, England) · 2020Article
- Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.Journal of hematology & oncology · 2020Article
- Aberrant WNT/CTNNB1 Signaling as a Therapeutic Target in Human Breast Cancer: Weighing the Evidence.Frontiers in cell and developmental biology · 2020Review
- RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.Journal of translational medicine · 2019Article
- Regional perturbation of gene transcription is associated with intrachromosomal rearrangements and gene fusion transcripts in high grade ovarian cancer.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRSPO ligands, activators of the Wnt/β-catenin pathway, are overexpressed in different cancers. The objective of this study was to investigate the role of RSPOs in breast cancer (BC).
methodsExpression of RSPO and markers of various cancer pathways were measured in breast tumours and cell lines by qRT-PCR. The effect of RSPO on the Wnt/β-catenin pathway activity was determined by luciferase assay, western blotting, and qRT-PCR. The effect of RSPO2 inhibition on proliferation was determined by using RSPO2 siRNAs. The effect of IWR-1, an inhibitor of the Wnt/β-catenin pathway, was examined on the growth of an RSPO2-positive patient-derived xenograft (PDX) model of metaplastic triple-negative BC.
resultsWe detected RSPO2 and RSPO4 overexpression levels in BC, particularly in triple-negative BC (TNBC), metaplastic BC, and triple-negative cell lines. Various mechanisms could account for this overexpression: presence of fusion transcripts involving RSPO, and amplification or hypomethylation of RSPO genes. Patients with RSPO2-overexpressing tumours have a poorer metastasis-free survival (P=3.6 × 10
conclusionsRSPO overexpression could therefore be a new prognostic biomarker and therapeutic target for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.